Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches.
Company profile
Ticker
CTKB
Exchange
Website
CEO
Wenbin Jiang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cytek (Shanghai) Biosciences Co., Ltd. • Cytek (Wuxi) Biosciences Co. Ltd. • Cytek Biosciences B.V. • Cytek Japan Corporation • Cytek Biosciences Ltd • Cytek Biosciences GmbH • Cytek Limited ...
IRS number
472547526
CTKB stock data
Latest filings (excl ownership)
8-K
Cytek® Biosciences Names William McCombe Chief Financial Officer
19 Mar 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
NT 10-K
Notice of late annual filing
1 Mar 24
8-K
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
1 Mar 24
8-K
Departure of Directors or Certain Officers
27 Feb 24
8-K
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
9 Jan 24
8-K
Regulation FD Disclosure
28 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
NT 10-Q
Notice of late quarterly filing
13 Nov 23
Transcripts
CTKB
Earnings call transcript
2023 Q4
28 Feb 24
CTKB
Earnings call transcript
2023 Q3
7 Nov 23
CTKB
Earnings call transcript
2023 Q2
8 Aug 23
CTKB
Earnings call transcript
2023 Q1
9 May 23
CTKB
Earnings call transcript
2022 Q3
9 Nov 22
CTKB
Earnings call transcript
2022 Q2
11 Aug 22
CTKB
Earnings call transcript
2022 Q1
12 May 22
CTKB
Earnings call transcript
2021 Q4
24 Feb 22
CTKB
Earnings call transcript
2021 Q3
8 Nov 21
Latest ownership filings
4
Ming Yan
11 Apr 24
144
Notice of proposed sale of securities
9 Apr 24
4
Philippe Busque
21 Mar 24
3
William D. McCombe
20 Mar 24
4
Ming Yan
19 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
Ming Yan
13 Mar 24
4
Paul Christopher Williams
13 Mar 24
4
Allen Poirson
13 Mar 24
4
Wenbin Jiang
13 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 163.63 mm | 163.63 mm | 163.63 mm | 163.63 mm | 163.63 mm | 163.63 mm |
Cash burn (monthly) | (no burn) | 14.82 mm | 2.14 mm | 1.97 mm | 1.41 mm | (no burn) |
Cash used (since last report) | n/a | 98.54 mm | 14.22 mm | 13.07 mm | 9.39 mm | n/a |
Cash remaining | n/a | 65.09 mm | 149.40 mm | 150.56 mm | 154.24 mm | n/a |
Runway (months of cash) | n/a | 4.4 | 69.8 | 76.6 | 109.2 | n/a |
Institutional ownership, Q3 2023
63.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 107 |
Opened positions | 18 |
Closed positions | 13 |
Increased positions | 54 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 411.69 bn |
Total shares | 83.05 mm |
Total puts | 9.30 k |
Total calls | 32.10 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 16.77 mm | $92.57 bn |
Brown Capital Management | 13.56 mm | $74.85 bn |
Vanguard | 11.08 mm | $61.16 bn |
Ra Capital Management | 6.81 mm | $37.59 bn |
Hillhouse Capital Advisors | 6.66 mm | $36.75 bn |
3E Bioventures Capital | 5.68 mm | $0.00 |
STT State Street | 3.78 mm | $20.85 bn |
Geode Capital Management | 2.35 mm | $13.00 bn |
New York State Common Retirement Fund | 2.35 mm | $12.96 mm |
Wellington Management | 1.45 mm | $7.98 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Ming Yan | Common Stock | Sell | Dispose S | No | Yes | 7.01 | 400 | 2.80 k | 6,008,502 |
9 Apr 24 | Ming Yan | Common Stock | Sell | Dispose S | No | Yes | 7 | 1,500 | 10.50 k | 6,008,902 |
20 Mar 24 | Philippe Busque | Common Stock | Payment of exercise | Dispose F | No | No | 6.7 | 2,129 | 14.26 k | 3,335 |
20 Mar 24 | Philippe Busque | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,464 | 0.00 | 5,464 |
20 Mar 24 | Philippe Busque | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,464 | 0.00 | 0 |
19 Mar 24 | Ming Yan | Common Stock | Sell | Dispose S | No | Yes | 6.71 | 20,000 | 134.20 k | 6,010,402 |
18 Mar 24 | Ming Yan | Common Stock | Sell | Dispose S | No | Yes | 6.77 | 20,000 | 135.40 k | 6,030,402 |
11 Mar 24 | Valerie Barnett | Common Stock | Payment of exercise | Dispose F | No | No | 7.22 | 1,912 | 13.80 k | 36,169 |
11 Mar 24 | Valerie Barnett | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,908 | 0.00 | 38,081 |
11 Mar 24 | Valerie Barnett | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,908 | 0.00 | 44,182 |
News
Cytek Biosciences Names William McCombe Chief Financial Officer; Reaffirms 2024 Revenue Outlook Of $203M-$213M Vs $207.86M Est.
19 Mar 24
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $10
6 Mar 24
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
4 Mar 24
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
Goldman Sachs Maintains Buy on Cytek Biosciences, Raises Price Target to $10
29 Feb 24
Press releases
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
7 Mar 24
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
28 Feb 24
Cytek Biosciences to Participate in Upcoming Investor Conferences
7 Feb 24